<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016053028176N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-06-23</date_registration>
      <primary_sponsor>Vice chancellor for research, Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of zinc supplementation on severe head trauma patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of zinc supplementation and plasebo on clinical improvement of severe head trauma patients admitted to ICU: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/22911</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: method of randomly allocation of the study is using random number tables.</study_design>
      <phase>2</phase>
      <hc_freetext>severe head trauma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention: 120 mg zinc elemental (528 mg zinc sulfat) as 20 ml zinc solution that were prepared by the study pharmacist in the Investigative Pharmacy Research Centre affiliated to Mashhad University of Medical Sciences Number of use: 2 times per day (10 ml at any time) for 15 days. Intervention 2: Control: 20 ml distilled water that were prepared by the study pharmacist in the Investigative Pharmacy Research Centre affiliated to Mashhad University of Medical Sciences Number of use: 2 times per day (10 ml at any time) for 15 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohamad safarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pardis ّAlley, Azadi Square</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>917794-8564</zip>
        <telephone>+98 51 3882 8888</telephone>
        <email>safarianM@mums.ac.ir</email>
        <affiliation>Faculty of Medicine, Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam khazdouz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Hemmat Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 45 3325 0610</telephone>
        <email>maryam.khazdouz@hotmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Severe head trauma patients; aged between 18 to 65 years; GCS between 6-8&#13;
&#13;
Exclusion criteria: patients undergoing a craniotomy; or with a medical history of liver, respiratory or renal disease; diabetes; hypertension and cardiovascular diseases; blood clotting problems; cancer and ongoing pregnancy; patients whit contraindication of enteral nutrition</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>(S00-S09)</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Injuries to the head</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention: 120 mg zinc elemental (528 mg zinc sulfat) as 20 ml zinc solution that were prepared by the study pharmacist in the Investigative Pharmacy Research Centre affiliated to Mashhad University of Medical Sciences Number of use: 2 times per day (10 ml at any time) for 15 days</i_keyword>
      <i_keyword>Control: 20 ml distilled water that were prepared by the study pharmacist in the Investigative Pharmacy Research Centre affiliated to Mashhad University of Medical Sciences Number of use: 2 times per day (10 ml at any time) for 15 days</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Glasgow outcome score (GCS). Timepoint: First 24 hours of admission, 7th, 16th and 28th day. Method of measurement: GCS table.</prim_outcome>
      <prim_outcome>Sequential Organ Failure Assessment (SOFA). Timepoint: First 24 h of admission, 7th and 16 th day. Method of measurement: SOFA table.</prim_outcome>
      <prim_outcome>Zinc plasma concentrations. Timepoint: First 24 hours of admission, 7th and 16th day. Method of measurement: Atomic absorption spectrophotometer.</prim_outcome>
      <prim_outcome>C-reactive protein (CRP). Timepoint: First 24 hours of admission and 16th day. Method of measurement: CRP ELISA Kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Copper plasma concentrations. Timepoint: first 24 hours of admission, 7th and 16th day. Method of measurement: Atomic absorption spectrophotometer.</sec_outcome>
      <sec_outcome>Length of hospital stay (LOS). Timepoint: at discharge day. Method of measurement: number of hospitalization days.</sec_outcome>
      <sec_outcome>Glasgow Outcome Score (GOS). Timepoint: At hospital discharge day. Method of measurement: GOS table.</sec_outcome>
      <sec_outcome>Erythrocyte sedimentation rate (ESR). Timepoint: First 24 hours of admission and 16th day. Method of measurement: Centrifuged.</sec_outcome>
      <sec_outcome>White blood cell (WBC) count. Timepoint: First 24 hours of admission and 16th day. Method of measurement: Conunt of WBC with cell counter.</sec_outcome>
      <sec_outcome>Mortality rate. Timepoint: At hospital discharge day. Method of measurement: Conunt of patients (dead and alive).</sec_outcome>
      <sec_outcome>Enteral  intake and parenteral administered. Timepoint: Daily. Method of measurement: Recods of amounts of intake.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-07-22</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Administration Center(Qoreishi Building) – Daneshgah St Mashhad  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
